Welcome to Closing the Gaps in Non-Small Cell Lung Cancer on ReachMD, sponsored by Lilly.
On today’s program, we’ll hear from Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center, who shares how he manages toxicities for his patients with non-small cell lung cancer. Here’s what Dr. Riess had to say.
So, in terms of managing toxicities for non-small cell lung cancer, it’s really broken down by what type of treatment they have.
So if they’re getting targeted therapies, many of them can cause rash, so giving patients prophylactic medications that they know to either get and start should they get early symptoms or to call once they get those symptoms.
If they’re concerned about anything, emphasizing that calling or sending a message early on, to not hesitate doing that and to be proactive about the management of those side effects.
For immunotherapy, it’s discussing the potential immune-related side effects and that they can manifest often in many different ways, so the patients to think about and be aware of that and to let us know right away if they’re having those symptoms.
And in terms of the multidisciplinary team, we have our nurse coordinator and nurse practitioners and so forth to work to bring patients in early before things get to a point of worsening in order to proactively treat those potential side effects.
Of course, there’s also, should things come up, our dermatologists and other subspecialists for immunotherapy—often endocrine dysfunction can occur—to get endocrinology and other subspecialists involved who are more and more familiar with these side effects.
So I would say overall the proactive education and management within a multidisciplinary team is absolutely key.
That was Dr. Riess sharing his approach to managing toxicities with the help of a multidisciplinary team. To revisit any part of this discussion and to access other episodes in this series, visit ReachMD.com/NSCLC, where you can Be Part of the Knowledge. Thanks for listening!